52494-53-8

Usage

Uses

Used in Pharmaceutical Research and Development:
6-Chloro-[1,2,4]triazolo[3,4-a]phthalazine is used as a chemical entity for exploring its potential biological activities and applications in the pharmaceutical industry. Its unique structure may offer novel avenues for drug discovery and development, particularly in the context of targeted therapies or as a scaffold for the design of new pharmaceutical agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-chloro-[1,2,4]triazolo[3,4-a]phthalazine is utilized as a starting point for the synthesis of new compounds with potential therapeutic effects. Its chemical properties, including the presence of the chlorine atom, may facilitate the attachment of various functional groups, enabling the creation of a diverse range of molecules with tailored pharmacological profiles.
Used in Drug Design:
6-Chloro-[1,2,4]triazolo[3,4-a]phthalazine is employed as a structural motif in drug design, where its tricyclic nature and chlorine substitution could be leveraged to enhance the binding affinity and selectivity of new drug candidates. 6-CHLORO-[1,2,4]TRIAZOLO[3,4-A]PHTHALAZINE may serve as a template for the development of molecules targeting specific biological receptors or enzymes, contributing to the advancement of personalized medicine.

InChI:InChI=1/C9H5ClN4/c10-8-6-3-1-2-4-7(6)9-12-11-5-14(9)13-8/h1-5H

Upstream product

• 85-44-9 phthalic anhydride 

Downstream Products

• 1567843-81-5 N-(4-fluorophenyl)-1,2,4-triazolo[3,4-a]phthalazin-6-amine 
• 677746-66-6 N-(4-chlorophenyl)-1,2,4-triazolo[3,4-a]phthalazin-6-amine 
• 677746-48-4 N-(4-methoxyphenyl)-1,2,4-triazolo[3,4-a]phthalazin-6-amine 
• 677746-47-3 N-(4-methylphenyl)-1,2,4-triazolo[3,4-a]phthalazin-6-amine 
• 21517-30-6 6-hydrazinyl-[1,2,4]triazolo[3,4-a]phthalazine 

Relevant academic research and scientific papers

3-substituted-6 - (1-substituted piperazinyl) - 1, 2, 4-triazole [3,4-a] [...] compound, preparation method thereof, and use thereof

The invention belongs to the field of medicinal chemistry and discloses a 3-substituted-6-(1-substituted piperazinyl)-1,2,4-triazoleo[3,4-a] phthalazine compound with antitumor activity as well as a preparation method and an application thereof. The compound has a structure as shown in a general formula I, wherein in the general formula I, R1 is hydrogen, methyl or phenyl; R2 is hydrogen, 4-fluorophenyl, 4-chlorphenyl, 3-trifluoromethylphenyl or 2-fluorophenyl. The preliminary in-vitro antitumor activity evaluation proves that the series of compounds have obvious effects of inhibiting and killing multiple tumor cells. The compound can serve as an active ingredient to be developed into a novel drug and is applied to clinical prevention and cancer therapy.

3,6-substituted -1, 2, 4-triazole [3,4-a] [...] compound and its preparation and use

The invention belongs to the field of medicinal chemistry, and discloses a 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound having antitumor activity as well as a synthesizing method and application of the 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound. The 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound has a structure as shown in a general formula I, wherein R1 refers to H, methyl or phenyl; R2 refers to 4-fluorophenyl, 4-chloroanilino, 4-bromophenyl, 4-methoxyphenyl, 4-hydroxydiphenyl, 2-fluorophenyl, 3-trifluoromethyl)phenyl]amino, naphthylamine-1-yl, pyrrolidone-1-yl, piperidine-1-yl, 3,5-dimethyl piperidine-1-yl, morpholine-4-yl, or piperazidine-1-yl. The preliminary in-vitro antitumor activity finds that the serial compounds have obvious inhibit and killing effects on multiple tumor cells, and the 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound can act as an active ingredient to be applied to clinical prevention and cancer treatment after being developed into a novel medicament.

Synthesis and antimicrobial activities of novel 1,2,4-triazolo [3,4-a] phthalazine derivatives

A series of novel 1,2,4-triazolo [3,4-a] phthalazine derivatives were synthesized in five steps from a common precursor, phthalic anhydride. Most of synthesized phthalazine derivatives showed inhibitory activity against Staphylococcus aureus. One of phthalazine derivatives 5l showed inhibitory activity against all tested bacterial and fungal strains.

Synthesis and positive inotropic evaluation of [1,2,4]triazolo[3,4-a] phthalazine and tetrazolo[5,1-a]phthalazine derivatives bearing substituted piperazine moieties

Four series of [1,2,4]triazolo[3,4-a]phthalazine and tetrazolo[5,1-a] phthalazine derivatives bearing substituted piperazine moieties were synthesized and evaluated for their positive inotropic activity by measuring the left atrium stroke volume in isolated rabbit-heart preparations. Several compounds were developed and showed favorable activities compared to the standard drug milrinone, with (4-([1,2,4]triazolo[3,4-a]phthalazin-6-yl)piperazin-1-yl)(p- tolyl)methanone (5g) being identified as the most potent with an increased stroke volume of 19.15 ± 0.22% (milrinone: 2.46 ± 0.07%) at a concentration of 3 × 10-5 M. A preliminary study of mechanism of action revealed that 5g displayed its positive inotropic effect may be related to the PDE-cAMP-PKA signaling pathway. Compounds exhibiting inotropic effects were also evaluated in terms of the chronotropic effects.

Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a] phthalazine derivatives

Trying to develop potent and selective anticancer agents, two series of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives were designed and synthesized. Their antitumor activities were evaluated by MTT method against four selected human cancer cell lines (MGC-803, EC-9706, HeLa and MCF-7). Our results showed that compound 11h exhibited good anticancer activities compared to 5-fluorouracil against the four tested cell lines, with IC50 values ranging from 2.0 to 4.5 μM. Flow cytometry analysis indicated that compound 11h induced the cellular early apoptosis and cell cycle arrest at G2/M phase in EC-9706.